Q4 2024 LivaNova PLC Earnings Call Transcript
Key Points
- LivaNova PLC (LIVN) achieved 11% organic revenue growth in 2024, marking the second consecutive year of double-digit organic growth.
- The company expanded operating margins and increased free cash flow, delivering $163 million in adjusted free cash flow for the full year 2024.
- Significant clinical milestones were achieved in obstructive sleep apnea (OSA) and difficult-to-treat depression (DTD), with the OSPREY clinical study meeting its primary efficacy and safety endpoints.
- LivaNova PLC (LIVN) successfully launched the ProtekDuo Plus in the US and Canada, strengthening its cardiopulmonary solutions.
- The company enhanced its executive leadership team and focused on talent development, with 30% of director-level positions filled by new hires or promotions.
- Epilepsy revenue in Europe and the rest of the world declined by a combined 9% in the fourth quarter of 2024, indicating challenges in international markets.
- The adjusted diluted earnings per share decreased to $0.81 from $0.87 in the fourth quarter of 2023, primarily due to a higher effective tax rate.
- The company faces ongoing litigation with the SNIA case, with potential financial implications not included in the 2025 guidance.
- Foreign exchange had an unfavorable impact on revenue, with a $3 million or 1% negative effect in the fourth quarter.
- The adjusted effective tax rate increased to 20% in the fourth quarter of 2024, compared to negative 3% in the same period of 2023, impacting net earnings.
Good day ladies and gentlemen, and welcome to the LivaNova PLC fourth quarter and full year 2024 and this conference call.
As a reminder, this conference call is being recorded.
I'd now like to introduce your host for today's conference, Ms. Briana Gotlin, LivaNova's Vice President of Investor Relations. Please go ahead.
Thank you and welcome to our conference call and webcast discussing LivaNova's financial results for the fourth quarter and full year of 2024. Joining me on today's call are Vladimir Makatsaria, our Chief Executive Officer and Member of the Board of Directors, Alex Shvartsburg, our Chief Financial Officer, Ahmet Tezel, our Chief Innovation Officer, and Zach Glazier, Director of Investor Relations.
Before we begin, I would like to remind you that the discussions during this call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
